This is the first study in the world to report the role of the BTLA inhibitor in combination with anti-PD-1 and chemotherapy as neoadjuvant treatment for locally advanced ESCC and as postoperative adjuvant IO-IO combination immunotherapy. This evidence concerns the gene BTLA and esophageal squamous cell carcinoma.